Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model

References

• Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 1978;30:255–68
   PubMed Web of Science ®Google Scholar
• Alvarez C, Marti-Bonmati L, Novella-Maestre E, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931–7
   PubMed Web of Science ®Google Scholar
• Soares SR. Etiology of OHSS and use of dopamine agonists. Fertil Steril 2012;97:3517–22
   Google Scholar
• Gomez R, Simon C, Remohi J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002;143:4339–48
   PubMed Web of Science ®Google Scholar
• Gomez R, Simon C, Remohí J, Pellicer A. Administration of moderate and high doses of gonadotrophins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod 2003;68:2164–71
   PubMed Web of Science ®Google Scholar
• Yan Z, Weich HA, Bernart W, et al. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J Clin Endocrinol Metab 1993;77:1723–5
   PubMed Web of Science ®Google Scholar
• Neulen J, Yan Z, Raczek S, et al. Human chorionic gonadotrophin-dependent expression of vascular endothelial growth factor/VP factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995;80:1967–71
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Konishi I, Tsuruta Y, et al. Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecol Endocrinol 1997;11:371–81
   PubMed Web of Science ®Google Scholar
• Wang TH, Horng SG, Chang CL, et al. Human chorionic gonadotrophin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 2002;87:3300–8
   PubMed Web of Science ®Google Scholar
• Knoepfelmacher M, Danilovic DL, Rosa Nasser RH, Mendonca BB. Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas. Fertil Steril 2006;86:15–18
   Web of Science ®Google Scholar
• Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2 dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006;147:5400–11
   PubMed Web of Science ®Google Scholar
• Lee KS, Kim SR, Park HS, et al. Csteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression. J Allergy Clin Immunol 2004;114:1093–9
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Ohba T, Tanaka N, et al. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats. Endocr J 2003;50:515–25
   PubMed Web of Science ®Google Scholar
• Saylan A, Arioz DT, Koken T, et al. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand 2010;89:692–9
   PubMed Web of Science ®Google Scholar
• Aboulghar M, Evers JH, Al-Inany H. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a cochrane review. Hum Reprod 2002;17:3027–32
   PubMed Web of Science ®Google Scholar
• Edwards RG. IVF, IVM, natural cycle IVF, minimal stimulation. Reprod Biomed Online 2007;15:106–19
   PubMed Web of Science ®Google Scholar
• Loutradis D, Kiapekou E, Zapanti E, Antsaklis A. Oocyte maturation in assisted reproductive techniques. Ann N Y Acad Sci 2006;1092:235–46
   PubMed Web of Science ®Google Scholar
• Abramov Y, Barae V, Nisman B, Schenker JG. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 1997;67:261–5
   PubMed Web of Science ®Google Scholar
• Gaytan M, Bellido C, Morales C, et al. Effects of selective inhibition of cyclooxygenase and lipooxygenase pathways in follicle rupture and ovulation in the rat. Reproduction 2006;132:571–7
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Shabadash V, Shen-Or Z, et al. The origin of ascites in the ovarian hyperstimulation syndrome is mainly ovarian in humans. Program and Abstracts of the Annual Meeting of the Society for Gynecological Investigation, San Diego, CA. (J Soc Gynecol Invest 1997:Abstract 123)
   Google Scholar
• Itskovitz-Eldor J, Kol S, Lewit N, Sealey JE. Ovarian origin of plasma and peritoneal fluid prorenin in early pregnancy and in patients with ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1997;82:461–4
   PubMed Web of Science ®Google Scholar
• Verheul HM, Hoekman K, Jorna AS, et al. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 2000;5:45–50
   PubMedGoogle Scholar
• Kamat BR, Brown LF, Manseau EJ, et al. Expression of vascular permeability factor/vascular endothelial growth factor by human granulose and theca/lutein cells. Role in corpus luteum development. Am J Pathol 1995;146:157–65
   PubMed Web of Science ®Google Scholar
• Youssef MA, van Wely M, Hassan MA, et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 2010;16:459–66
   PubMed Web of Science ®Google Scholar
• Tehraninejad ES, Hafezi M, Arabipoor A, et al. Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. J Assist Reprod Genet 2012;29:259–64
   PubMed Web of Science ®Google Scholar
• Quintana R, Kopcow L, Marconi G, et al. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarianhyperstimulation syndrome in a rat model. Fertil Steril 2008;90:1511–16
   PubMed Web of Science ®Google Scholar
• Engin-Ustun Y, Yılmaz S, Timur H, et al. Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model. Gynecol Endocrinol 2013;29:851–4
   PubMed Web of Science ®Google Scholar
• Eli AM, Quintana R, Carrere C, et al. Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study. J Ovarian Res 2013;6:62–70
   PubMedGoogle Scholar
• Salhab AS, Gharaibeh MN, Shomaf MS, Amro BI. Meloxicam inhibits rabbit ovulation. Contraception 2001;63:329–33
   PubMed Web of Science ®Google Scholar
• Athanasiou S, Bourne TH, Khalid A, et al. Effects of indomethacin on follicular structure, vascularity, and function ovary the periovulatory period in women. Fertil Steril 1996;65:556–60
   PubMed Web of Science ®Google Scholar
• Sato S, Itamochi H. Bevacizumab and ovarian cancer. Curr Opin Obstet Gynecol 2012;24:8–13
   PubMed Web of Science ®Google Scholar
• Murphy RC, Gijon MA. Biosynthesis and metabolism of leukotrienes. Biochem J 2007;405:379–395
   PubMed Web of Science ®Google Scholar
• Henderson Jr WR. The role of leukotrienes in asthma. Ann Allergy 1994;72:272–8
   PubMedGoogle Scholar
• Arakawa H, Lotvall J, Kawikova I, et al. Leukotriene D4- and prostaglandin F2 alpha-induced airflow obstruction and airway plasma exudation in guinea-pig: role of thromboxane and its receptor. Br J Pharmacol 1993;110:127–32
   PubMed Web of Science ®Google Scholar
• Lee KS, Kim SR, Park HS, et al. Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression. J Allergy Clin Immunol 2004;114:1093–9
   PubMed Web of Science ®Google Scholar
• Korzekwa AJ, Acosta TJ, Miklewicz M, et al. Leukotrienes affect secretory function of ovarian cells in vitro. Reprod Domest Anim 2010;45:288–96
   Web of Science ®Google Scholar